Next Science Ltd
ASX:NXS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.125
0.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Next Science Ltd
Next Science Ltd
Cash & Cash Equivalents
Next Science Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Next Science Ltd
ASX:NXS
|
Cash & Cash Equivalents
$9.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Cash & Cash Equivalents
AU$23.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
|
Polynovo Ltd
ASX:PNV
|
Cash & Cash Equivalents
AU$45.9m
|
CAGR 3-Years
81%
|
CAGR 5-Years
27%
|
CAGR 10-Years
55%
|
|
|
SDI Ltd
ASX:SDI
|
Cash & Cash Equivalents
AU$6.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Cash & Cash Equivalents
AU$30.8m
|
CAGR 3-Years
94%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Cash & Cash Equivalents
$185.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-5%
|
|
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
What is Next Science Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
9.2m
USD
Based on the financial report for Dec 31, 2023, Next Science Ltd's Cash & Cash Equivalents amounts to 9.2m USD.
What is Next Science Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
5%
Over the last year, the Cash & Cash Equivalents growth was 82%. The average annual Cash & Cash Equivalents growth rates for Next Science Ltd have been 4% over the past three years , 5% over the past five years .
You don't have any saved screeners yet
